1.43

0.70% 0.01

Pre-market: 1.41 -0.02 -1.40%

Mersana Therapeutics Inc (MRSN)

Overview News Price History Option Chain Financials Discussions Forecast

Mersana Therapeutics Inc stock is traded at $1.43, with a volume of 1.42M. It is up +0.70% in the last 24 hours and down -37.28% over the past month. Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Previous Close:

$1.42

Open:

$1.42

24h Volume:

1.42M

Relative Volume:

1.24

Market Cap:

$176.65M

Revenue:

$36.86M

Net Income/Loss:

$-171.67M

P/E Ratio:

-0.701

EPS:

-2.04

Net Cash Flow:

$-171.05M

1W Performance:

-11.73%

1M Performance:

-37.28%

6M Performance:

-28.86%

1Y Performance:

-38.36%

1-Day Range:

$1.35

$1.46

1-Week Range:

$1.35

$1.61

52-Week Range:

$1.22

$6.2801

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name

Mersana Therapeutics Inc

Sector

Healthcare (1173)

Industry

Biotechnology (670)

Phone

617-498-0020

Address

840 MEMORIAL DRIVE, CAMBRIDGE

Employee

123

Twitter

@MersanaADC

Next Earnings Date

2024-11-05

Latest SEC Filings

MRSN's Discussions on Twitter

Compare MRSN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MRSN Mersana Therapeutics Inc	1.43	176.65M	36.86M	-171.67M	-171.05M	-1.50
VRTX Vertex Pharmaceuticals Inc	402.70	103.71B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	712.33	78.28B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	615.00	36.77B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	235.31	30.35B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.95	27.32B	3.30B	-501.07M	1.03B	-2.1146

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-15-24	Resumed	Citigroup	Buy
Mar-19-24	Upgrade	JP Morgan	Underweight → Neutral
Feb-29-24	Upgrade	BTIG Research	Neutral → Buy
Feb-29-24	Upgrade	Guggenheim	Neutral → Buy
Feb-29-24	Upgrade	Wedbush	Neutral → Outperform
Dec-04-23	Upgrade	Citigroup	Neutral → Buy
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-27-23	Downgrade	BTIG Research	Buy → Neutral
Jul-27-23	Downgrade	Citigroup	Buy → Neutral
Jul-27-23	Downgrade	Guggenheim	Buy → Neutral
Jul-27-23	Downgrade	JP Morgan	Neutral → Underweight
Jul-27-23	Downgrade	Truist	Buy → Hold
Jul-27-23	Downgrade	Wedbush	Outperform → Neutral
Jun-16-23	Downgrade	JP Morgan	Overweight → Neutral
Jun-15-23	Initiated	Guggenheim	Buy
Mar-16-23	Upgrade	JP Morgan	Neutral → Overweight
Jan-20-23	Initiated	Citigroup	Buy
Nov-21-22	Initiated	Truist	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Aug-30-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	Credit Suisse	Neutral
Dec-03-20	Initiated	Stifel	Buy
Sep-29-20	Resumed	JP Morgan	Neutral
Apr-29-20	Initiated	BTIG Research	Buy
Jan-21-20	Reiterated	H.C. Wainwright	Buy
Mar-11-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-18	Upgrade	Leerink Partners	Mkt Perform → Outperform
May-08-18	Initiated	Robert W. Baird	Outperform
Mar-19-18	Downgrade	JP Morgan	Overweight → Neutral

View All

Mersana Therapeutics Inc Stock (MRSN) Latest News

Dec 31, 2024

Barclays PLC Increases Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 31, 2024

Dec 30, 2024

State Street Corp Has $5.15 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 30, 2024

Dec 28, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 28, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Dec 28, 2024

Dec 19, 2024

Fmr LLC Acquires 32,332 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 19, 2024

Mersana Therapeutics: We're About To Find Out If Their ADC Platform Is More Tolerable - Seeking Alpha

Dec 19, 2024

Dec 15, 2024

BNP Paribas Financial Markets Sells 98,881 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Dec 15, 2024

Dec 13, 2024

XTX Topco Ltd Acquires 225,823 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 13, 2024

Dec 08, 2024

Jacobs Levy Equity Management Inc. Has $1.88 Million Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 08, 2024

Dec 06, 2024

Verition Fund Management LLC Increases Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Dec 06, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Atom Investors LP - MarketBeat

Dec 06, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Target Price from Analysts - Defense World

Dec 06, 2024

Dec 03, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 03, 2024

Dec 01, 2024

Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Price Is Right But Growth Is Lacking After Shares Rocket 25% - Simply Wall St

Dec 01, 2024

Nov 28, 2024

Acuta Capital Partners LLC Sells 463,000 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - MarketBeat

Nov 28, 2024

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) 3-Year EBITDA Growth Rate : -0.50% (As of Sep. 2024) - GuruFocus.com

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) Future 3-5Y EPS without NRI Growth Rate : 17.91 (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Mersana Therapeutics (FRA:0M4) Forward Dividend Yield % : 0.00% (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Nov 23, 2024